OCA is a semisynthetic bile acid analogue and a potent farnesoid X receptor (FXR) agonist, approved by the NICE in 2017 as a second-line agent for patients with PBC who exhibit an inadequate biochemical response to UDCA or are unable to tolerate it [8]. The gene discussed is NR1H4; the disease is primary biliary cholangitis.